Effect of Warfarin Treatment on Survival of Patients with Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL)

Circulation

Trial (n=187 on warfarin and 187 matched controls) found no significant survival advantage was observed in patients on warfarin. In patients with PAH linked to systemic sclerosis, long-term warfarin was associated with poorer survival than in patients not on warfarin.

Clinical outcomes in patients with ST-segment elevation myocardial infarction treated with everolimus-eluting stents versus bare-metal stents (EXAMINATION): 5-year results of a randomised trial

The Lancet

RCT (n=1498) found patient-oriented endpoint occurred in 159 (21%) patients in the everolimus-eluting stents group vs. 192 (26%) in the bare-metal stents group (HR 0.80, 95% CI 0.65–0.98; p=0.033). This difference was mainly driven by a reduced rate of all-cause mortality.

Closure versus medical therapy for preventing recurrent stroke in patients with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack

Cochrane Database of Systematic Reviews

The combined data from recent RCTs have shown no statistically significant differences between these interventions in prevention of recurrent ischaemic stroke.

Treatment and Outcome of Thrombolysis-Related Hemorrhage: A Multicenter Retrospective Study

JAMA Neurology

This US study of 128 patients with symptomatic intracerebral haemorrhage following thrombolysis for ischaemic stroke reports a median time to diagnosis of 470 minutes and highlights a role for cryoprecipitate in reversing recombinant tissue plasminogen activator coagulopathy.

The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at:
http://www.evidence.nhs.uk/about-evidence-services/content-and-sources/medicines-information/new-medicines-awareness-services